Enpatoran Shows Promise for Lupus Skin Symptoms in Mid-Stage Trial, But Experts Urge Caution

An experimental oral medication called enpatoran is showing encouraging results for treating the skin symptoms of lupus, according to a new mid-stage clinical trial. However, some experts say the data is not yet strong enough to declare a clear winner among the different doses tested.

The drug works by blocking two specific targets in the immune system known as Toll-like receptors 7 and 8 (TLR7 and TLR8). Researchers believe these receptors play a key role in triggering the inflammation that causes lupus flare-ups, particularly in the skin. The study, published in The Lancet Rheumatology, suggests that enpatoran could become a new option for people living with cutaneous lupus, a form of the disease that primarily affects the skin.

But as with many promising treatments, the road from clinical trial to pharmacy shelf is long, and the results come with important caveats.

What the Study Found: A Closer Look at the Numbers

The trial, named WILLOW, was a phase II dose-finding study. This means its main goal was to figure out which dose of enpatoran works best and is safest. Researchers enrolled 102 patients who had significant lupus-related skin disease. These participants were split into four groups: one received a placebo (a dummy pill), and the other three received either 25 mg, 50 mg, or 100 mg of enpatoran twice daily.

The main measure of success was a tool called the Cutaneous Lupus Disease Area and Severity Index-Activity, or CLASI-A. This is a 70-point scale doctors use to score how active and severe a patient’s lupus skin rash is. A higher score means worse symptoms.

After 16 weeks, the results were striking:

– Patients taking 25 mg of enpatoran saw their CLASI-A scores drop by 64 percentage points from the start of the study.

• Those on 50 mg saw a 72 percentage point reduction.
• Those on 100 mg saw a 68 percentage point reduction.
• By comparison, the placebo group saw only a 44 percentage point reduction.

All three doses were statistically better than placebo, meaning the results were unlikely to be due to chance. The lead researcher, Dr. Eric Morand of Monash University in Australia, and his team also found a “dose-response relationship.” In simple terms, this means that for every increase in dose, patients got about 4 additional percentage points of improvement in their CLASI-A scores. The statistical significance for this trend was strong (P <0.0002).

Based on these findings, the researchers concluded that enpatoran is effective enough to move forward into larger, phase III trials. Those trials, called ELOWEN-1 and ELOWEN-2, are already underway. They will test the 50 mg twice-daily dose in about 200 patients each, comparing it against placebo.

Why Experts Are Not Fully Convinced

Despite the promising numbers, not everyone is ready to celebrate. In an accompanying commentary in the same journal, Dr. Cristina Arriens of the Oklahoma Medical Research Foundation raised several red flags.

Her main concern: the confidence intervals around the CLASI-A scores for each dose overlapped considerably. Confidence intervals are a statistical tool that shows the range where the true effect likely lies. When they overlap as much as they did in this study, it becomes very difficult to say that one dose is truly better than another. Dr. Arriens stated that the “data were insufficient to clearly differentiate between the doses.”

She also pointed to a graph in the study paper that suggests the highest dose (100 mg) might not have actually produced the best results. In fact, the 50 mg dose appeared to perform slightly better than the 100 mg dose on the primary skin measure.

This is not the first time enpatoran’s dose-response has been questioned. Earlier this year, results from another part of the same phase II trial (called Cohort B) were published. That portion tested the same three doses in patients with systemic lupus erythematosus (SLE), which can affect many parts of the body, not just the skin. In that analysis, researchers could find no clear dose-response relationship. If anything, the lowest dose seemed to work the best.

These mixed signals highlight the challenges of drug development. A drug can show an overall benefit, but finding the “sweet spot” dose—where effectiveness is high and side effects are low—is often tricky.

How This Affects People Living with Lupus

For the roughly 5 million people worldwide living with lupus, news of a potential new treatment is always welcome. Lupus is a chronic autoimmune disease, meaning the body’s immune system attacks its own healthy tissues. Cutaneous lupus erythematosus (CLE) is a form of the disease that primarily causes skin rashes, sores, and lesions. These can be painful, disfiguring, and deeply affect a person’s quality of life.

Current treatments for lupus skin disease often include:

• Topical steroids or immune-modulating creams
• Antimalarial drugs like hydroxychloroquine
• Oral steroids (corticosteroids) for flare-ups
• Stronger immunosuppressants like methotrexate, mycophenolate, or azathioprine

Many of these treatments come with significant side effects, especially when used long-term. Steroids, for example, can cause weight gain, bone thinning, and increased infection risk. So there is a real need for new, better-tolerated options.

Enpatoran works differently. It targets TLR7 and TLR8, which are part of the body’s “innate” immune system—the first line of defense against germs. In lupus, these receptors are overactive. They trigger the release of inflammatory proteins called interferons and activate B-cells, which produce autoantibodies that attack the body. By blocking TLR7 and TLR8, enpatoran aims to quiet this immune overreaction at its source.

Dr. Morand and his team called enpatoran “well tolerated” in the study. The most common side effect was upper respiratory infections, which were slightly more common in the higher-dose groups. Other side effects included diarrhea, urinary tract infections, shingles (herpes zoster), and elevated liver enzymes. However, the number of patients affected was very small—often just one or two per group.

Safety Signals and the Need for Larger Studies

One pattern that did catch experts’ attention was the side effect profile. There appeared to be a potential dose-response for adverse effects as well. In the 100 mg group:

• 8% of patients experienced grade 3 or 4 (serious) adverse events, compared to 4% in the lower-dose groups.
• 8% of patients in the high-dose group stopped taking the drug because of side effects, compared to 0-4% in the placebo and lower-dose groups.

However, it is important to keep these numbers in perspective. With only about 25 people per group, 8% represents just two patients. That is far too small a sample to draw firm conclusions about safety. The ongoing phase III trials, which will enroll roughly 200 patients per group, will provide much more reliable data on whether enpatoran is truly safe at the 50 mg dose.

For now, the safety profile looks reasonable, but doctors and patients will want to see more data before feeling confident.

Practical Takeaways for Readers

If you or a loved one is living with lupus, especially the skin form of the disease, here is what you need to know:

• Enpatoran is not yet approved. It is still an investigational drug. Do not expect to see it in pharmacies anytime soon. Phase III trials typically take one to three years to complete, followed by regulatory review.
• The 50 mg dose seems to be the frontrunner. Based on the balance of effectiveness and side effects, the phase III trials are testing 50 mg twice daily. This dose showed the best numerical improvement in skin scores and had a lower rate of serious side effects than the 100 mg dose.
• Talk to your rheumatologist or dermatologist. If you have difficult-to-treat lupus skin disease, ask your doctor if there are any clinical trials for enpatoran or other new treatments in your area. You can search for trials at ClinicalTrials.gov.
• Do not stop your current medications. Until enpatoran is proven safe and effective in larger studies, standard treatments remain the best option. Never change your lupus medication regimen without talking to your doctor.
• Stay hopeful but realistic. The fact that enpatoran has moved to phase III trials is a positive sign. The drug targets a new biological pathway, which could mean it works for patients who do not respond to existing therapies. But many promising drugs fail in larger trials, so it is too early to declare victory.

The Bottom Line

Enpatoran is a promising new drug that targets TLR7 and TLR8, key drivers of inflammation in lupus. A mid-stage trial showed it significantly reduced skin symptoms compared to placebo. However, experts caution that the data did not clearly show which dose is best, and safety data is still very limited.

The larger phase III trials (ELOWEN-1 and ELOWEN-2) will be critical. They will test the 50 mg dose in hundreds of patients and should provide clearer answers about both effectiveness and safety. For now, enpatoran represents hope—but not yet a cure—for the millions of people living with the painful skin symptoms of lupus.

Source: MedPage Today